pre-miRNA Information | |
---|---|
pre-miRNA | mmu-mir-325 |
Genomic Coordinates | chrX: 105379082 - 105379179 |
Synonyms | Mirn325, mmu-mir-325, Mir325 |
Description | Mus musculus miR-325 stem-loop |
Comment | None |
RNA Secondary Structure |
Mature miRNA Information | |
---|---|
Mature miRNA | mmu-miR-325-3p |
Sequence | 54| UUUAUUGAGCACCUCCUAUCAA |75 |
Evidence | Experimental |
Experiments | Cloned |
Putative Targets |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | Atp11b | ||||||||||||||||||||
Synonyms | 1110019I14Rik, ATPIF, ATPIR, mKIAA0956 | ||||||||||||||||||||
Description | ATPase, class VI, type 11B | ||||||||||||||||||||
Transcript | NM_029570 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on Atp11b | |||||||||||||||||||||
3'UTR of Atp11b (miRNA target sites are highlighted) |
>Atp11b|NM_029570|3'UTR 1 AGGGACAGTAGGACTTTGTGGAACAAGTTCACTTGTCCTCAGGTTTGGGGTCACCATCCAGTTGTAAAAGGCCAGTTACT 81 TTCTGAAATCTCTTGAGGAATTGACACTTTCTCAGAGTCCATGGGAAACAGGCAGTTATATGAACCCTTCTCCTTTCTCT 161 TTAATTTGAATGTGAATATATTAAAATTTGGAGATAAAGAGATAGTAACAATCTCTTTGTCTGGTTTGTCCCTTCTGATC 241 ATGGGACTCCTGGTGGCATTGCAGCCTTTGCTGAGGCCACTGTACTTTAATATCAAGGTAGAGAAAGGGGTCATTCTTGG 321 TTATGTGTAGTTTAAGATGAGGGTGGTTTGGGACTCTTCTATTTAAATCTGCTTCTGTAAATTTTGCTAAAGATTTGCCT 401 TGAGAACTCTATTTTTTTTATTAGATTATATTTGAAGCTTTTCGTGGGGAAAGTTAATGTGAATATCAAGGAATTTTGGT 481 CCTTCAGTGACCTCTGTTAATTCATTAGTACTTTTTAAGTCACAGAGCAACTAGGAGAGCACGTTTCTAACCACTGTCTT 561 TTGCGGTGTGGGTAATAAGCTTATACTGACCCCACTTCTTTAACGATGCTGTAACCCAGCCAGTGACGCTAATCCTACAA 641 GTGCAAAGGGAGTTTTGCATCTCATGTCCAAGTCAGAATTAGGGCCATTTACTAGACTTCAAATTGGTGTTTGCTAATAT 721 TTTTGTGGCCAAGTATGTAAACTTGTAGTGGGTAAATTCAATACTTTTGTCATATTAATTTACTGTATCTGTCTTATCTT 801 TTGCATGCTTCAACCTGGCTAATATATTTAAATCCACCGCATCTCTCCTCCCTCCCCCCATTATTACTTTCCTCTCTCTC 881 CAAAGACTCTGTTCATAGTTTTATAACAATATTGTAAAGTTCAATTGTATCAATAAAAAAAAAAAACAAGTTTGGACAGT 961 ATTTAAATATTGCAAATATATTTAATTATATAAATTAAAATATAAGCCATAATGTCTTTCTTTGGCCCACTTAGAATTGC 1041 TCTTGACTTGCTGTAAACCAACCTTCAGAATAAAGGACTTTTGTTAAGAAAAAAAAAAAAAAAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
Experimental Support 1 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | CD4+ T cells (C57BL/6) |
Disease | MIMAT0004640 |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
"HITS-CLIP data was present in GSM1013594. RNA binding protein: AGO2. Condition:CD4+ T cells
"HITS-CLIP data was present in GSM1013595. RNA binding protein: AGO2. Condition:CD4+ T cells
... - Loeb GB; Khan AA; Canner D; Hiatt JB; et al., 2012, Molecular cell. |
Article |
- Loeb GB; Khan AA; Canner D; Hiatt JB; et al. - Molecular cell, 2012
MicroRNAs (miRNAs) are essential components of gene regulation, but identification of miRNA targets remains a major challenge. Most target prediction and discovery relies on perfect complementarity of the miRNA seed to the 3' untranslated region (UTR). However, it is unclear to what extent miRNAs target sites without seed matches. Here, we performed a transcriptome-wide identification of the endogenous targets of a single miRNA-miR-155-in a genetically controlled manner. We found that approximately 40% of miR-155-dependent Argonaute binding occurs at sites without perfect seed matches. The majority of these noncanonical sites feature extensive complementarity to the miRNA seed with one mismatch. These noncanonical sites confer regulation of gene expression, albeit less potently than canonical sites. Thus, noncanonical miRNA binding sites are widespread, often contain seed-like motifs, and can regulate gene expression, generating a continuum of targeting and regulation.
LinkOut: [PMID: 23142080]
|
27 mmu-miR-325-3p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT054600 | Arc | activity regulated cytoskeletal-associated protein | 3 | 1 | ||||||||
MIRT577829 | Rinl | Ras and Rab interactor-like | 1 | 1 | ||||||||
MIRT577905 | Prr11 | proline rich 11 | 1 | 1 | ||||||||
MIRT578380 | Krtap6-1 | keratin associated protein 6-1 | 1 | 1 | ||||||||
MIRT578550 | Hsd17b1 | hydroxysteroid (17-beta) dehydrogenase 1 | 1 | 1 | ||||||||
MIRT578770 | Gemin8 | gem nuclear organelle associated protein 8 | 1 | 1 | ||||||||
MIRT580288 | Trhr | thyrotropin releasing hormone receptor | 1 | 1 | ||||||||
MIRT581518 | Ptprd | protein tyrosine phosphatase, receptor type, D | 1 | 1 | ||||||||
MIRT582779 | Kif1c | kinesin family member 1C | 1 | 1 | ||||||||
MIRT585752 | Stard6 | StAR-related lipid transfer (START) domain containing 6 | 1 | 1 | ||||||||
MIRT587310 | Ephx3 | epoxide hydrolase 3 | 1 | 4 | ||||||||
MIRT588735 | Taok3 | TAO kinase 3 | 1 | 1 | ||||||||
MIRT592550 | Mup7 | major urinary protein 7 | 1 | 1 | ||||||||
MIRT592592 | Mup13 | major urinary protein 13 | 1 | 1 | ||||||||
MIRT594207 | Wdr12 | WD repeat domain 12 | 1 | 1 | ||||||||
MIRT594462 | Epyc | epiphycan | 1 | 1 | ||||||||
MIRT594693 | Atp11b | ATPase, class VI, type 11B | 1 | 1 | ||||||||
MIRT594929 | Gjb2 | gap junction protein, beta 2 | 1 | 1 | ||||||||
MIRT594934 | Frem3 | Fras1 related extracellular matrix protein 3 | 1 | 1 | ||||||||
MIRT595784 | Hlf | hepatic leukemia factor | 1 | 1 | ||||||||
MIRT595846 | Set | SET nuclear oncogene | 1 | 1 | ||||||||
MIRT595897 | Cd69 | CD69 antigen | 1 | 1 | ||||||||
MIRT603010 | Klk8 | kallikrein related-peptidase 8 | 1 | 1 | ||||||||
MIRT603579 | Ppm1k | protein phosphatase 1K (PP2C domain containing) | 1 | 1 | ||||||||
MIRT604052 | Esf1 | ESF1 nucleolar pre-rRNA processing protein homolog | 1 | 1 | ||||||||
MIRT736870 | GHRHR | growth hormone releasing hormone receptor | 2 | 0 | ||||||||
MIRT756335 | Gsdmd | gasdermin D | 3 | 1 |
miRNA-Drug Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|